LOGIN  |  REGISTER
Chimerix

List of Biotech and Pharma Companies Using Artificial Intelligence

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 136.04
0.47 0.35
2.83M
4.45B
US$ 605.380B
US$ 129.49
-1.60 -1.22
4.62M
2.53B
US$ 327.610B
US$ 157.06
-1.20 -0.76
3.18M
1.77B
US$ 278.000B
US$ 31.60
-0.19 -0.60
1.75M
6.38B
US$ 201.610B
US$ 82.29
0.91 1.12
8.57M
1.33B
US$ 109.450B
US$ 318.70
3.38 1.07
747,883
261.91M
US$ 83.470B
US$ 560.73
2.70 0.48
415,317
129.99M
US$ 72.890B
US$ 228.79
-1.56 -0.68
1.30M
289.01M
US$ 66.120B
US$ 166.61
2.60 1.59
4.94M
383.24M
US$ 63.850B
US$ 127.37
1.77 1.41
2.27M
397.68M
US$ 50.650B
US$ 516.50
0.40 0.08
264,934
82.59M
US$ 42.660B
US$ 229.60
2.51 1.11
710,126
182.20M
US$ 41.830B
US$ 79.85
0.52 0.66
1.43M
456.46M
US$ 36.450B
US$ 203.89
-0.69 -0.34
575,546
161.61M
US$ 32.950B
US$ 96.95
-2.05 -2.07
1.23M
240.99M
US$ 23.360B
US$ 16.60
-0.16 -0.95
6.33M
1.13B
US$ 18.760B
US$ 73.80
-0.19 -0.26
1.26M
233.38M
US$ 17.220B
US$ 141.28
1.24 0.89
597,961
111.09M
US$ 15.690B
US$ 21.25
0.73 3.56
621,852
586.83M
US$ 12.470B
US$ 77.25
0.55 0.72
762,764
145.34M
US$ 11.230B
US$ 217.21
-0.34 -0.16
301,855
51.51M
US$ 11.190B
US$ 24.87
0.22 0.89
1.30M
437.17M
US$ 10.870B
US$ 43.73
0.56 1.30
602,713
221.85M
US$ 9.700B
US$ 12.48
0.34 2.80
1.38M
421.26M
US$ 5.260B
US$ 29.04
0.44 1.54
836,743
173.82M
US$ 5.050B
US$ 7.20
0.09 1.27
1.14M
679.09M
US$ 4.890B
US$ 58.54
0.89 1.54
384,289
73.88M
US$ 4.320B
US$ 22.00
-1.60 -6.78
2.25M
148.60M
US$ 3.270B
US$ 16.73
0.20 1.21
372,468
160.84M
US$ 2.690B
US$ 25.55
-0.15 -0.58
1.47M
89.37M
US$ 2.280B
US$ 9.56
0.09 0.95
2.29M
228.22M
US$ 2.180B
US$ 17.31
1.20 7.45
1.15M
119.32M
US$ 2.070B
US$ 11.48
0.03 0.26
4.16M
169.59M
US$ 1.950B
US$ 0.66
0.0046 0.70
44.44M
1.71B
US$ 1.130B
C$ 3.73
0.02 0.54
240,120
238.21M
C$ 888.520M
US$ 7.55
0.74 10.87
226,004
107.64M
US$ 812.700M
US$ 24.37
0.63 2.65
123,033
27.61M
US$ 672.860M
US$ 4.69
-0.04 -0.85
381,516
126.38M
US$ 592.720M
US$ 8.43
-0.16 -1.86
919,959
57.79M
US$ 487.170M
US$ 2.86
0.09 3.25
1.46M
169.68M
US$ 485.280M
US$ 4.21
-0.14 -3.22
852,704
113.08M
US$ 476.070M
US$ 27.58
-0.39 -1.39
93,137
14.21M
US$ 391.910M
US$ 4.73
-0.01 -0.21
10,440
65.38M
US$ 309.250M
US$ 12.94
0.64 5.20
168,066
18.18M
US$ 235.250M
US$ 1.42
0.10 7.58
1.13M
143.67M
US$ 204.010M
US$ 1.01
-0.02 -1.94
975,557
184.28M
US$ 186.120M
US$ 15.34
0.03 0.20
36,243
6.33M
US$ 97.100M
US$ 5.05
-0.28 -5.25
49,652
19.08M
US$ 96.350M
US$ 1.63
0.09 5.84
52,176
47.95M
US$ 78.160M
US$ 2.72
0.02 0.74
314,336
26.33M
US$ 71.620M
US$ 1.07
0.04 3.88
646,474
66.86M
US$ 71.540M
US$ 6.23
0.00 0.00
103,702
10.76M
US$ 67.030M
US$ 0.75
-0.02 -2.59
32,675
77.23M
US$ 57.910M
US$ 1.14
0.02 1.79
712,144
48.97M
US$ 55.830M
US$ 0.88
0.02 2.09
18,865
56.95M
US$ 50.060M
C$ 0.46
0.02 4.55
28,274
101.40M
C$ 46.640M
US$ 1.58
-0.03 -1.86
63,854
26.37M
US$ 41.660M
US$ 2.54
-0.15 -5.58
374,071
16.12M
US$ 40.940M
C$ 0.22
-0.005 -2.22
41,000
156.82M
C$ 34.500M
C$ 0.53
-0.02 -3.64
19,500
65.05M
C$ 34.480M
US$ 1.11
0.00 0.00
32,008
26.32M
US$ 29.220M
US$ 1.62
-0.01 -0.61
160,494
17.48M
US$ 28.320M
US$ 2.13
-0.06 -2.74
41,449
12.43M
US$ 26.480M
US$ 2.98
0.05 1.71
33,736
7.85M
US$ 23.390M
US$ 4.04
0.16 4.12
29,315
5.41M
US$ 21.860M
US$ 1.73
0.10 6.13
81,493
11.98M
US$ 20.730M
US$ 2.19
-0.03 -1.13
70,177
8.62M
US$ 18.880M
C$ 0.27
0.02 8.00
37,000
66.55M
C$ 17.970M
US$ 0.65
0.02 3.14
48,619
25.46M
US$ 16.540M
US$ 0.69
-0.01 -2.03
81,531
21.59M
US$ 14.810M
C$ 0.19
0.00 0.00
0
74.18M
C$ 13.720M
C$ 0.03
0.00 0.00
350,412
535.30M
C$ 13.380M
US$ 2.27
0.00 0.00
9,699
5.85M
US$ 13.280M
US$ 0.89
0.005 0.57
70,378
14.78M
US$ 13.080M
US$ 0.27
-0.0017 -0.62
191,141
47.97M
US$ 12.970M
US$ 0.57
0.0089 1.58
69,440
21.89M
US$ 12.510M
US$ 2.46
0.02 0.82
8,476
4.99M
US$ 12.280M
US$ 0.70
0.02 2.21
40,976
16.85M
US$ 11.780M
US$ 1.19
-0.02 -1.65
39,118
9.31M
US$ 11.080M
US$ 0.63
-0.02 -2.64
28,043
16.82M
US$ 10.530M
US$ 1.40
0.06 4.48
100,698
5.59M
US$ 7.830M
US$ 1.06
-0.20 -15.87
400,795
6.14M
US$ 6.510M
US$ 1.57
-0.05 -3.06
33,070
4.10M
US$ 6.430M
US$ 0.82
0.0033 0.40
69,848
7.29M
US$ 5.980M
US$ 1.22
0.06 5.17
30,284
4.89M
US$ 5.970M
C$ 0.08
-0.005 -5.88
25,000
69.83M
C$ 5.590M
US$ 0.61
-0.0035 -0.57
56,106
6.88M
US$ 4.200M
US$ 6.20
0.67 12.12
247,410
655,616
US$ 4.060M
C$ 0.02
0.00 0.00
481,061
246.29M
C$ 3.690M
US$ 1.13
-0.03 -2.59
35,533
3.10M
US$ 3.500M
US$ 0.70
-0.04 -5.97
91,558
4.65M
US$ 3.280M
US$ 0.39
-0.0026 -0.67
45,878
6.01M
US$ 2.330M
C$ 0.02
0.00 0.00
0
89.59M
C$ 1.790M
US$ 0.05
-0.06 -52.52
11,400
28.90M
US$ 1.440M
US$ 4.72
0.00 0.00
44,633
-
US$ -
C$ 0.16
0.00 0.00
17,857
-
C$ -
C$ 1.72
0.00 0.00
524,233
-
C$ -
US$ 6.74
0.00 0.00
110,339
-
US$ -

Latest News From Biotech and Pharma Companies Using Artificial Intelligence



HEALWELL AI’s Pentavere Partners with Sunnybrook and Successfully Demonstrates its AI Powered Clinician Co-pilot System Can Improve Cancer Staging in Prestigious Peer-Reviewed Medical Journal

Pentavere partnered with Sunnybrook Health Sciences Centre to demonstrate how Pentavere’s DARWEN™ AI platform can help enhance cancer staging to improve patient outcomes. Results of this collaboration were presented at the prestigious American Head and Neck Society annual conference and published in JAMA Otolaryngology, which is the highest impact journal for Otolaryngologic or ‘head and neck’ cancers. This is the first published paper of its kind demonstrating... Read more


HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio

Southlake, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it has been granted Indian Patent Application 201817014481 by the Indian Patent Office (IPO). To date, HeartSciences has been... Read more


HeartBeam’s Artificial Intelligence Algorithm Combined with Vectorcardiography (VCG) Outperforms Expert Cardiologists in Detecting Arrhythmias

New Data Presented at Heart Rhythm Society Conference Demonstrates Continued Progress with Company’s AI Program Data Show That Applying AI to VCG Data Provides More Consistent and Reliable Detection of Atrial Flutter SANTA CLARA, Calif. / May 20, 2024 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced new study data demonstrating that HeartBeam... Read more


BullFrog AI and Lieber Institute for Brain Development Collaboration Identifies Novel Drug Targets for Neuropsychiatric Disorders

GAITHERSBURG, Md., May 16, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug discovery company using artificial intelligence (AI) and machine learning to enable the successful discovery and development of pharmaceuticals and biologics, today announced significant advancements in its collaboration with the Lieber Institute for Brain Development (LIBD), including the identification... Read more


HEALWELL AI Participates in Leading-Edge Research on Chronic Kidney Disease Highlighting the Potential of its AI Powered Clinical Co-Pilot

HEAWELL AI’s Clinical Co-Pilot technology participated in recently published evidence showing the integration of a highly accurate machine model for Chronic Kidney Disease (“CKD”) progression when paired with Electronic Health Record (“EHR”) linked clinical decision support, improves guideline-recommended testing in patients with CKD. HEALWELL’s subsidiary Khure Health (“Khure”) co-authored an abstract that was published this month in the American Journal... Read more


American Oncology Network Advances Karyogram Segmentation and Increases the Speed to Results with New A.I. Software

FORT MYERS, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC), one of the nation’s fastest-growing community oncology networks, and the AON Central Lab are pleased to announce the implementation of the new cytogenetics A.I. software HiBand v8.4 for karyogram segmentation and classification. AON Central Lab is the first laboratory in the world to utilize this technology.   Cytogenetics A.I. leverages machine learning to screen... Read more



Rakovina Therapeutics Announces Extensions and Expansions of Strategic Collaborations to Support AI Research

VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the expansion of two research collaborations to align with its recently announced collaboration with the Deep Docking AI Drug Discovery Platform. On March 27, 2024, the Company announced... Read more


Ventripoint Diagnostics' Next Generation, AI-powered Heart-scanning Technology Submitted to U.S Food and Drug Administration

VMS+4.0 submitted to FDA on May 1 for clearance  Ventripoint will market new advances after FDA clearance  Toronto, Ontario – TheNewswire - May 6, 2024 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) has reached another development milestone by submitting its next generation of software, VMS+4.0, to the U.S. Food and Drug Administration (“FDA”). This latest advance of Ventripoint’s AI-powered technology,... Read more


Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

XCE853 is Oregon Therapeutic’s first-in-class, and potentially best-in-class PDI inhibitor, exhibiting potent preclinical efficacy across multiple solid and hematological cancers, and is ready to advance to Investigational New Drug (IND)-enabling development. The AI-enabled collaboration aims to refine and expand the positioning of XCE853, a novel protein disulfide isomerase (PDI) inhibitor, in new and targeted oncology indications, including for drug-resistant tumors. The... Read more


WELL Health Technologies Launches its Second-Generation AI powered Physician Co-pilot with Chronic Disease Detection Powered by HEALWELL AI

WELL and HEALWELL AI have launched the second-generation of WELL AI Decision Support ("WAIDS"), which now features advanced chronic disease screening for diseases like chronic kidney disease, hypertension, and diabetes, enabling patient risk stratification. The updated WAIDS tool identifies over one hundred diseases and delivers actionable clinical insights at the point of care, contributing to the management of chronic disease-related costs in Canada, which... Read more


GE HealthCare Launches New Era of AI-Enhanced, Personalized Oncology Solutions at ESTRO 2024 Congress

Company unveiling innovations which harness the power of AI to optimize the complex radiation therapy workflow and enable personalized, more timely care for patients across the cancer care continuum CHICAGO / May 01, 2024 / Business Wire / GE HealthCare (Nasdaq: GEHC) today announced Revolution RT,i a new radiation therapy computed tomography (CT) solution with innovative hardware and software solutions to help increase imaging accuracy, while simplifying simulation... Read more


Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI

Transaction is part of wide-ranging collaboration to combine Quest's oncology expertise and scale with PathAI's AI and digital pathology innovations to speed diagnosis, improve quality and reduce costs SECAUCUS, N.J. and BOSTON, May 1, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology, today announced a multi-faceted collaboration... Read more


Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics

LOS ANGELES and AMSTERDAM, April 30, 2024 (GLOBE NEWSWIRE) -- RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (Nasdaq: RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model contributing to its mission to transform early cancer diagnostics. Leveraging ultra-low pass whole genome sequencing (ULP-WGS) of cell-free DNA (cfDNA), Flamingo represents a promising leap forward... Read more


Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal...

Groundbreaking topline results demonstrated sensitivity for colorectal cancer of 92% with specificity of 90% and best-in-class sensitivity for advanced adenoma of 82% 690 subjects analyzed including previously unexamined and reported patients from Company’s ColoFuture and eAArly DETECT studies utilizing the mRNA biomarkers, FIT test, and a proprietary AI Algorithm The power to determine advanced adenoma, lesions in a pre-cancerous stage, can change the entire CRC... Read more


Moderna and OpenAI Collaborate To Advance mRNA Medicine

Generative AI will help advance Moderna's broad and diverse portfolio to maximize the Company's impact on patients Moderna embeds OpenAI's generative AI tools throughout its organization and sees early success with broad adoption of ChatGPT Enterprise CAMBRIDGE, MA AND SAN FRANCISCO, CA / ACCESSWIRE / April 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) and OpenAI today announced their ongoing collaboration to co-innovate with a shared vision of AI's transformative potential... Read more


Augmedix Launches Industry’s First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency Departments

SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced the general availability of Augmedix Go for emergency departments (EDs), marking the launch of the industry’s first fully-automated, generative AI (GenAI) powered medical documentation product for EDs across the country. The launch incorporates learnings from a pilot program with HCA Healthcare (NYSE: HCA), one of... Read more


ThinkSono Releases Real-Time DVT AI Training Solution for Butterfly Network's Handheld Ultrasound Devices

LONDON, ENGLAND / ACCESSWIRE / April 23, 2024 / ThinkSono, a pioneering provider of AI-driven medical imaging solutions, is proud to announce the release of ThinkSono AI Training, a deep vein thrombosis (DVT) training application developed through a Butterfly Garden™ partnership with Butterfly Network, Inc. ("Butterfly") (NYSE: BFLY), a digital health company transforming care with the power of portable, semiconductor-based ultrasound technology and intuitive softwar... Read more


GE HealthCare Introduces AI-Enhanced Voluson Signature 20 and 18 Ultrasound Systems to Advance Women’s Health Imaging

Integrated artificial intelligence (AI) and advanced tools improve image quality and exam speed to help providers make accurate diagnoses and tailor precision care for women Latest Voluson Signature ultrasound technology offers an intuitive and ergonomic design allowing clinicians to focus on patient care CHICAGO / Apr 18, 2024 / Business Wire / GE HealthCare (Nasdaq: GEHC) today announced the launch of the Voluson Signature 20 and 18 ultrasound systems, which comp... Read more


Veeva Systems Launches AI Partner Program

Advanced technology and support to enable the development of GenAI solutions PLEASANTON, Calif., April 18, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced the Veeva AI Partner Program to provide partners with the advanced technology and support needed to integrate Generative AI (GenAI) solutions seamlessly with Veeva Vault applications. "Our customers are exploring GenAI solutions across many use cases as the technology evolves," said... Read more


Bionano Genomics and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence

Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology. Their joint endeavor aims to commercialize the first ever cytogenetic workflow that integrates OGM plus AI chromosome karyotype analysis Diagens will become an original... Read more


SOPHiA GENETICS Announces Unilabs is using its AI Technology to Detect Homologous Recombination Deficiency (HRD)

European-based Unilabs has deployed the SOPHiA DDM™ Platform across its network in Switzerland to support cancer diagnostics and treatment BOSTON and ROLLE, Switzerland, April 17, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Unilabs, one of the largest diagnostic providers in Europe, and the only provider to offer laboratory, imaging and pathology specialties... Read more


ProPhase Labs Unveils Project ZenQ-AI

Leveraging ProPhase Labs’ AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company’s... Read more


Charles River Laboratories and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology

Powered by digital pathology and AI algorithms, Patholytix Foresight drives speed and quality in toxicologic pathology practices WILMINGTON, Mass. & DUBLIN / Apr 11, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex, an innovator in pathology AI. By combining Deciphex’s unique... Read more


Netramark's AI-Based Clinical Solution Identifies Novel Lung And Colon Cancer Biomarkers And Patient Subpopulations

Insights open the door for potential precision immunotherapy innovation targeting novel pathways and patient enrichment strategies with the potential to improve clinical trial success rates  TORONTO, April 10, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, announces the presentation of new data describing how its proprietary NetraAI... Read more


Medtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care

AI-driven solutions and strategic alliances showcase Medtronic's promise to enhance the efficiency and effectiveness of endoscopy DUBLIN, April 10, 2024 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system, along with a strategic collaboration... Read more


Ginkgo Bioworks Awarded Grant for AI-enabled Forecasting of Measles Outbreaks

Ginkgo epidemiological modeling experts and Northeastern University researchers awarded new grant from the Bill & Melinda Gates Foundation BOSTON, April 10, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has been awarded a grant from the Bill & Melinda Gates Foundation to build an open-access, AI-enabled measles forecasting model to empower proactive public... Read more


HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias

New Data Presented at the European Heart Rhythm Association Conference Marks First Scientific Presentation on HeartBeam AI, the Company’s Deep Learning Technology Data Shows HeartBeam AI Combined with VCG Greatly Improves Detection of Atrial Flutter over Single-Lead ECGs Found in Leading Smartwatches and Other Wearables SANTA CLARA, Calif. / Apr 09, 2024 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac... Read more


iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation

Provides a holistic breast health solution, including breast cancer screening focused on quality, safety and efficiency, breast cancer detection, breast density assessment, and risk evaluation Expands access to iCAD’s AI-powered ProFound Breast Health Suite and Densitas’ AI solutions to patients and medical professionals worldwide NASHUA, N.H. and HALIFAX, Nova Scotia, April 09, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically... Read more


Augmedix Integrates with Andor Health to Revolutionize Ambient Clinical Documentation for Ambulatory Virtual Care

SAN FRANCISCO and ORLANDO, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- In a significant move to streamline healthcare workflows and allow clinicians to focus on patient care, Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, announced today that it has integrated with Andor Health, an AI-first cloud-based communication and collaboration platform for virtual care. The alliance aims to harness the power of ambient documentation to transform... Read more


iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting

NASHUA, N.H., April 08, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today that new data indicates its AI-powered solution effectively uncovers calcium deposits in the breast vessels, a sign of possible cardiovascular disease in women. iCAD research collaborator Chirag Parghi, M.D., Chief Medical Officer of Solis Mammography, presented the findings at the American College of Cardiology... Read more


Nanalysis Scientific Receives Funding Supporting AI Software Development for Detection of Illicit Substances

CALGARY, AB, April 4, 2024 /CNW/ - Nanalysis Scientific Corp. ("the Company" or "Nanalysis", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR machines, MRI technology for industrial and research applications, and detection equipment services, announces that its subsidiary Nanalysis Corp. is receiving advisory services and up to $1.45 million in non-repayable, non-dilutive funding from the National Research Council of Canada Industrial Research Assistance... Read more


Allurion Technologies Expands Virtual Care Suite to the United States

Virtual Care Suite (VCS) is now available to license in the United States for providers offering GLP-1 and other anti-obesity medication therapy, bariatric surgery, and weight loss devices US product launch to kick off at the Obesity Medicine Conference in Denver on April 25 NATICK, Mass. / Apr 04, 2024 / Business Wire / Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the commercial availability of its comprehensive Virtual... Read more


Healthcare Triangle Announces Strategic Partnership with Cynomi to Enhance Cybersecurity in Healthcare

PLEASANTON, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” “HCTI” or the “Company”), a leading provider of healthcare IT solutions, is thrilled to announce its partnership with Cynomi, a pioneer vCISO platform vendor. This collaboration introduces an innovative Virtual Chief Information Security Officer (vCISO) service tailored specifically for the healthcare provider market, setting a new standard... Read more


HEALWELL AI’s Pentavere Achieves Validation of Generative AI for Preventative Care Through Landmark Publication

Pentavere has published industry’s first peer-reviewed paper utilizing AI and large language models (or LLMs) to identify rare lung cancer patients. Industry applications may include Real World Evidence generation, identification of areas of unmet clinical need and optimization of cancer therapy and care pathways. Pentavere is an AI-powered patient identification company and this validated instance of identifying cancer patients using LLMs for preventative care purposes... Read more


GE HealthCare Introduces Caption AI on Vscan Air SL Wireless Handheld Ultrasound System to Help More Clinicians Capture Diagnostic-Quality Cardiac Images

Caption AI on Vscan Air SL expands access to cardiac care by enabling more medical professionals to feel confident acquiring images for rapid assessments AutoEF feature automatically calculates ejection fraction, saving time for clinicians while delivering key information for making their diagnoses GE HealthCare to debut new technology at 2024 American College of Cardiology Annual Scientific Session & Expo, April 6 – 8, 2024 in Atlanta CHICAGO / Apr 03, 2024... Read more


Healthcare Triangle Breaks New Ground in AI-Powered Patient Data Management with readabl.ai

PLEASANTON, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” “HCTI” or the “Company”), In a pioneering move, a leading health system has partnered with Healthcare Triangle to utilize a groundbreaking cloud-based AI and machine learning solution. This collaboration establishes a revolutionary benchmark in the management and utilization of patient data, ultimately elevating the standards for enhanced care... Read more


iCAD Partners with RAD-AID to Advance Breast Cancer Detection Using AI in Underserved Regions and Low- and Middle-Income Countries (LMICs)

NASHUA, N.H., April 03, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, is proud to announce a philanthropic global health collaboration with RAD-AID International. RAD-AID, a non-profit charitable organization dedicated to improving radiology healthcare in medically underserved regions, is collaborating with iCAD to introduce mammography AI-based decision support in LMICs, starting with an... Read more


iCAD Unveils ProFound Cloud, Enabling Interoperability and Access to Breast AI Solutions at Enterprise Scale

NASHUA, N.H., April 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, today announced commercial availability of ProFound Cloud. The innovative Software-as-a-Service (SaaS) platform provides medical providers with a cost-effective, secure, and scalable means to access and deploy the latest ProFound Breast Health Suite of AI solutions. “With the commercial launch of ProFound Cloud, iCAD is... Read more


InterSystems and ImmunoPrecise Antibodies' Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications

VICTORIA, British Columbia / Mar 28, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and speed challenges, together with ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, are thrilled to announce... Read more


Rakovina Therapeutics Announces Strategic Pivot to AI

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage response inhibitor therapeutics, is pleased to announce a strategic evolution in its business model that will place the Company at the forefront of artificial intelligence-driven (AI) precision medicine for... Read more


Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment

Merveille.ai Files Patent for Obesity Treatment, Begins Preparatory Steps for Clinical Trials, Joins Nvidia Developer Program NEW YORK, March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, is excited to announce a significant breakthrough by its subsidiary, Merveille.ai, in the field of obesity treatment. Utilizing advanced artificial intelligence, Merveille.ai has identified a promising new therapeutic... Read more


GE HealthCare Unveils AI-Enabled Urology Software Feature Prostate Volume Assist

Prostate Volume Assist (PVA) is the company’s proprietary urology-based artificial intelligence (AI) software feature designed to automate the manual process for generating prostate volume measurements New AI software feature will be available for use on the bkActiv, bk3000/5000 and bkSpecto active imaging systems Addition of AI solution advances leadership in urological active imaging CHICAGO / Mar 27, 2024 / Business Wire / GE HealthCare (Nasdaq: GEHC) today announced... Read more


iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments  iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets  Concurrent $15M PIPE financing, announced yesterday, extends cash runway through fiscal year 2025 and provides support for collaboration  Company to host webcasted conference call today at 8:30 a.m. EDT to... Read more


Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform

CHICAGO, IL / ACCESSWIRE / March 21, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the initiation of the development of Cloudscreen 2.0, the new iteration of its groundbreaking Artificial... Read more


Ontrak Health Announces Launch of Ontrak Advanced Engagement System, Ushering in the Next Era of AI-enabled Behavioral Healthcare

MIAMI / Mar 21, 2024 / Business Wire / Ontrak Health (NASDAQ: OTRK), a leading AI-powered and tech-enabled behavioral healthcare company, today announced the launch of its Ontrak Advanced Engagement System. This system integrates Augmented Intelligence (AI) with an evidence-based clinical framework to deliver human-centered, personalized member engagement. Built on a foundation of real-world AI application, the Ontrak Advanced Engagement System enables member engagement... Read more


ImmunoPrecise Antibodies Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments

Significant throughput of LSA to advance IPA’s diversity- and data-driven drug development and to enrich LENSai™. VICTORIA, British Columbia / Mar 20, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it has acquired the LSA® instrument platform from Carterra®, a leading provider of high-throughput large... Read more


Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider

Petros begins enrollment in AI integrated Human Factors Study to optimize self-screening, continuing its efforts to make STENDRA (avanafil) the first erectile dysfunction medication to achieve OTC Status Please see important safety information below NEW YORK, NY / ACCESSWIRE / March 19, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces... Read more


GE HealthCare Accelerates AI Innovation with Healthcare-Specific Foundation Models Powered by NVIDIA

Using NVIDIA Technology, SonoSAMTrack¹ demonstrates its pliability and applicability in ultrasound image segmentation, consistently delivering high-quality results over a wide range of demanding datasets and conditions SAN JOSE, Calif. / Mar 18, 2024 / Business Wire / Building on a long-term artificial intelligence (AI) collaboration, GE HealthCare used NVIDIA technology to develop its recent research model SonoSAMTrack1, which combines a promptable foundation model... Read more

COPYRIGHT ©2023 HEALTH STOCKS HUB